Companies · Healthtech

Tabula Rasa HealthCare, Inc.

Moorestown · Healthtech · refined from filed group “Other Health Care

Diligence memoA one-page analyst read on Tabula Rasa HealthCare, Inc. — recommendation, valuation, rhythm, risks.
$109.3M
Total raised · real
5
Rounds
1.6×
Latest step-up
Top 5%
Sector rank · raised
Series C
Latest stage · inferred · Mon Oct 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Tabula Rasa HealthCare, Inc. looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the healthtech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.53× the median modeled value of Series C Healthtech companies in 2019–2021 (33 peers) — value vs value, same stage and era.
Dormant
  • Last raise 5.7 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Healthtech

Tabula Rasa HealthCare, Inc. is one of 2138 Healthtech companies tracked from Moorestown. By capital raised it ranks among the largest (ahead of 96% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
1
Investors (latest)
2020-10-05
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$500M$1.0B$1.5B$2.0BSeries C · 2017-09-06 Raised $53M (real) Modeled valuation $1.3B (est)$53M$1.3BSeries C2017Series C · 2018-08-31 Raised $3.5M (real) Modeled valuation $90M (est)$3.5M$90MSeries C2018Series C · 2018-10-19 Raised $14M (real) Modeled valuation $363M (est)$14M$363MSeries C2018Series C · 2019-01-02 Raised $15M (real) Modeled valuation $384M (est)$15M$384MSeries C2019Series C · 2020-10-05 Raised $24M (real) Modeled valuation $573M (est)$24M$573MSeries C2020+$3.5M+$14M+$15M+$24MCumulative $109M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series C$52.5M · 2017
Series C extension$3.5M · 2018
Series C extension$14.2M · 2018
Series C extension$15.0M · 2019
Series C extension$24.1M · 2020

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series A, Series B — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 20%.

Modeled valuation trajectory
$573.1M
Base estimate est.
$87.5M
Conservative case
$1.5B
Upside case
$160.6M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ca $40M–$100M round). Valuation is modeled from stage benchmarks scaled by the healthtech sector profile. Directional, not a quoted figure.

Series C · modeled $1.3B · 2017-09-062017Series C · modeled $89.5M · 2018-08-31Series C · modeled $363.2M · 2018-10-19Series C · modeled $383.6M · 2019-01-02Series C · modeled $573.1M · 2020-10-052020
Model inputs · modeled:benchmark-stage-stepup-v1
15%
Dilution assumption
Implied ownership sold in the financing.
73%
Survival probability
55% low · 85% high
1.32×/yr
Annual markup
1.51×/yr upside case
5.7 yr
Elapsed time used
5.7 yr actual, capped for stale marks
healthtech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
9 mo
Avg between rounds
$35.5M/yr
Capital velocity
8.8 yr
On record since
2017
First round
5
Rounds on file
How it compares to the market

Benchmarked against 2138 companies in Healthtech. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 25× above median
This company$109.3M
Sector median$4.5M
Latest round — vs other Series C rounds in sector (real $, this stage) 0.5× of median
This company$24.1M
Sector median$46.5M
Modeled value — vs sector median (estimate, all stages) 17× above median
This company$573.1M
Sector median$33.8M

Raised more than 96% of sector peers (real $). Modeled value above 94% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series C) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #29 of 33.

This companyCohort peer
$100.0M$1.0B$10.0B$10.0M$100.0M$1.0BCapital raised (log)Virta Health Corp. · Series C Raised $122.0M · modeled $2.4B (est)Fresenius Medical Care Voorhees, LLC · Series C Raised $71.1M · modeled $1.8B (est)Clear Health Pass Holdings LLC · Series C Raised $100.0M · modeled $1.8B (est)Zealth, Inc. · Series C Raised $95.0M · modeled $1.7B (est)Jawbone Health Hub, Inc. · Series C Raised $65.4M · modeled $1.7B (est)Boston Health Economic Holdings, LLC · Series C Raised $63.0M · modeled $1.6B (est)PWN Health Holdings, Inc. · Series C Raised $61.8M · modeled $1.5B (est)Quartet Health, Inc. · Series C Raised $127.0M · modeled $1.4B (est)Workit Health, Inc. · Series C Raised $87.9M · modeled $1.4B (est)Ajax Health II LLC · Series C Raised $51.0M · modeled $1.3B (est)Eden Health, Inc. · Series C Raised $73.4M · modeled $1.3B (est)NeuSpera Medical Inc. · Series C Raised $88.6M · modeled $1.3B (est)Tabula Rasa HealthCare, Inc. (this company) Raised $109.3M · modeled $573.1M (est)Tabula Rasa HealthCare, Inc.
CompanyStageRaised · realValue · estvs peer med.
Virta Health Corp.Series C$122.0M$2.4B2.19×
Fresenius Medical Care Voorhees, LLCSeries C$71.1M$1.8B1.67×
Clear Health Pass Holdings LLCSeries C$100.0M$1.8B1.67×
Zealth, Inc.Series C$95.0M$1.7B1.55×
Jawbone Health Hub, Inc.Series C$65.4M$1.7B1.54×
Boston Health Economic Holdings, LLCSeries C$63.0M$1.6B1.48×
PWN Health Holdings, Inc.Series C$61.8M$1.5B1.39×
Quartet Health, Inc.Series C$127.0M$1.4B1.29×
Workit Health, Inc.Series C$87.9M$1.4B1.27×
Ajax Health II LLCSeries C$51.0M$1.3B1.20×
Eden Health, Inc.Series C$73.4M$1.3B1.19×
NeuSpera Medical Inc.Series C$88.6M$1.3B1.19×
Tabula Rasa HealthCare, Inc. this companySeries C$109.3M$573.1M0.53×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series C$52.5M2017-09-06$350.0M$1.3B90%
Series C$3.5M2018-08-31$23.3M$89.5M90%
Series C$14.2M2018-10-19$94.7M$363.2M90%
Series C$15.0M2019-01-02$100.0M$383.6M90%
Series C$24.1M2020-10-05$160.6M$573.1M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series C$52.5M2017-09-06
    • First recorded raise — entered as Series C.
    • 36 investors on this round.
  2. Series C$3.5M2018-08-31
    • Raised 12 mo later, in step with the ~14 mo sector norm.
    • Round 15.0× smaller than the prior — bridge or down round.
    • 3 investors on this round.
  3. Series C$14.2M2018-10-19
    • Came back fast: 2 mo vs the ~14 mo sector norm.
    • Round 4.1× larger than the prior — scaling up.
    • 2 investors on this round.
  4. Series C$15.0M2019-01-02
    • Came back fast: 2 mo vs the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 8 investors on this round.
  5. Series C$24.1M2020-10-05
    • Raised again after 21 mo — slower than the ~14 mo sector norm.
    • Round 1.6× larger than the prior — scaling up.
    • 1 investor on this round.
Intelligence
2021 ~Q3
Modeled next raise · ~9mo cadence
$38.7M
Modeled next size est.range $25.1M$61.9M
1.6×
Last step-up
$35.5M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Calvin H. Knowlton1 other2017-09
A. Gordon Tunstall2017-09
Brian H. Adams2017-09
Bruce V. Luehrs2017-09
Daniel H. Lubin2017-09
Dennis H. Helling2018-08
Dennis V. Heling2017-09
Glen H. Bressner2017-09
Jan Gordon Berger2018-08
Kathrine Gordon O'Brien2019-01
Michael Gordon Purcell2018-08
Orsula H. Knowlton2017-09
Samira H. Beckwith2018-08
Samira Kanaan Beckwith2017-09
Schweitzer Gordon Pamela2020-10
Registry & provenance

Tabula Rasa HealthCare, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1651561
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Gt Medical Technologies, Inc.HealthtechSeries C$114.5M$396.5Msame sector · same stage
HighFive Healthcare TopCo, LLCHealthtechSeries C$100.7M$601.3Msame sector · same stage
Convergent Dental, Inc.HealthtechSeries C$99.1M$119.8Msame sector · same stage
Elevate Care International Topco LPHealthtechSeries C$98.4M$1.0Bsame sector · same stage
Trice Medical, Inc.HealthtechSeries C$124.2M$115.8Msame sector · same stage
Akura Medical, Inc.HealthtechSeries C$94.8M$299.6Msame sector · same stage
Magnolia Medical Technologies, Inc.HealthtechSeries C$94.2M$728.3Msame sector · same stage
Genome Medical Holding CoHealthtechSeries C$90.0M$606.2Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Tabu Health, Inc.HealthtechSeed$83.6M85%
Cala Health, Inc.HealthtechSeries C$370.1M84%
Tula Health, Inc.HealthtechSeries B$37.3M83%
Sana Health, Inc.HealthtechSeries A$128.9M82%
Prism Care Inc.HealthtechPre-Seed$1.9M82%
Amphora Medical, Inc.HealthtechSeries A$248.6M82%
Covera Health, Inc.HealthtechSeries B$485.3M82%
Auxira Health, Inc.HealthtechSeries A$24.0M81%
Frequently asked
How much funding has Tabula Rasa HealthCare, Inc. raised?
Tabula Rasa HealthCare, Inc. has raised approximately $109.3M in disclosed capital across 5 recorded financing rounds, aggregated from public filings.
What is Tabula Rasa HealthCare, Inc.'s estimated valuation?
Provath's modeled valuation for Tabula Rasa HealthCare, Inc. is approximately $573.1M (modeled range $87.5M–$1.5B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Tabula Rasa HealthCare, Inc. at?
Tabula Rasa HealthCare, Inc.'s latest modeled financing stage is Series C. Its most recent recorded round closed around Mon Oct 05.
What does Tabula Rasa HealthCare, Inc. do and where is it based?
Tabula Rasa HealthCare, Inc. operates in the Healthtech sector, based in Moorestown.
Explore related

See where Tabula Rasa HealthCare, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Tabula Rasa HealthCare, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.